In vitro inhibitory effects of non-steroidal anti-inflammatory drugs on 4-methylumbelliferone glucuronidation in recombinant human UDP-glucuronosyltransferase 1A9 - Potent inhibition by niflumic acid

Biopharmaceutics and Drug Disposition

Volumn 27, Issue 1, 2006, Pages 1-6

  Mano, Yuji ^a   Usui, Takashi ^a   Kamimura, Hidetaka ^a  

^a ASTELLAS PHARMA INC   (Japan)

Author keywords

4 methylumbelliferone; Inhibition; Niflumic acid; NSAIDs; UGT1A9

Indexed keywords

DICLOFENAC; DIFLUNISAL; GLUCURONOSYLTRANSFERASE; HYMECROMONE; INDOMETACIN; KETOPROFEN; NAPROXEN; NIFLUMIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; RECOMBINANT ENZYME;

ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG GLUCURONIDATION; DRUG POTENCY; ENZYME INHIBITION; IC 50; IN VITRO STUDY; MICHAELIS MENTEN KINETICS;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DICLOFENAC; DIFLUNISAL; ENZYME INHIBITORS; GLUCURONIDES; GLUCURONOSYLTRANSFERASE; HUMANS; HYMECROMONE; KINETICS; NIFLUMIC ACID; RECOMBINANT PROTEINS;

EID: 31744443743     PISSN: 01422782     EISSN: None     Source Type: Journal    
DOI: 10.1002/bdd.475     Document Type: Article

References (20)

1. Strassburg CP, Manns MP, Tukey RH. Expression of the UDP-glucuronosyltransferase 1A locus in human colon. Identification and characterization of the novel extra-hepatic UGT1A8. J Biol Chem 1998; 273: 8719-8726.
2. Gaiser BK, Lockley DJ, Staines AG, Baarnhielm C, Burchell B. Almokalant glucuronidation in human liver and kidney microsomes: evidence for the involvement of UGT1A9 and 2B7. Xenobiotica 2003; 33: 1073-1083.
3. Wynalda MA, Wynalda, KM, Amore BM, Fagerness PE, Wienkers LC. Characterization of bropirimine O-glucuronidation in human liver microsomes. Xenobiotica 2003; 33: 999-1011.
4. Ramirez J, Iyer L, Journault K, et al. In vitro characterization of hepatic flavopiridol metabolism using human liver microsomes and recombinant UGT enzymes. Pharm Res 2002; 19: 588-594.
5. Hanioka N, Ozawa S, Jinno H, Ando M, Saito Y, Sawada J. Human liver UDP-glucuronosyltransferase isoforms involved in the glucuronidation of 7-ethyl-10-hydroxycamptothecin. Xenobiotica 2001; 31: 687-699.
6. Girard H, Court MH, Bernard O, et al. Identification of common polymorphisms in the promoter of the UGT1A9 gene: evidence that UGT1A9 protein and activity levels are strongly genetically controlled in the liver. Pharmacogenetics 2004; 14: 501-515.
7. Miners JO, Mackenzie PI. Drug glucuronidation in humans. Pharmacol Ther 1991; 51: 347-369.
8. Court MH, Duan SX, von Moltke LL, et al. Interindividual variability in acetaminophen glucuronidation by human liver microsomes: identification of relevant acetaminophen UDP-glucuronosyltransferase isoforms. J Pharmacol Exp Ther 2001; 299: 998-1006.
9. King C, Tang W, Ngui J, Tephly T, Braun M. Characterization of rat and human UDP-glucuronosyltransferases responsible for the in vitro glucuronidation of diclofenac. Toxicol Sci 2001; 61: 49-53.
10. Sakaguchi K, Green M, Stock N, Reger TS, Zunic J, King C. Glucuronidation of carboxylic acid containing compounds by UDP-glucuronosyltransferase isoforms. Arch Biochem Biophys 2004; 424: 219-225.
11. Mano Y, Usui T, Kamimura H. Effect of β-estradiol and propofol on the 4-methylumbelliferone glucuronidation in recombinant human UGT isozymes 1A1, 1A8 and 1A9. Biopharm Drug Dispos 2004; 25: 339-344.
12. Margolis JM, Obach RS. Impact of nonspecific binding to microsomes and phospholipid, on the inhibition of cytochrome P4502D6: implications for relating in vitro inhibition data to in vivo drug interactions. Drug Metab Dispos 2003; 31: 606-611.
13. Vietri M, Pietrabissa A, Mosca F, Pacifici GM. Mycophenolic acid glucuronidation and its inhibition by non-steroidal anti-inflammatory drugs in human liver and kidney. Eur J Clin Pharmacol 2000; 56: 659-664.
14. Vietri M, Pietrabissa A, Mosca F, Pacifici GM. Inhibition of mycophenolic acid glucuronidation by niflumic acid in human liver microsomes. Eur J Clin Pharmacol 2002; 58: 93-97.
15. Picard N, Ratanasavanh D, Premaud A, Le Meur Y, Marquet P. Identification of the UDP-glucuronosyltransferase isoforms involved in mycophenolic acid phase II metabolism. Drug Metab Dispos 2005; 33: 139-146.
16. Mano Y, Usui T, Kamimura H. In vitro inhibitory effects of non-steroidal anti-inflammatory drugs on UDP-glucuronosyltransferase 1A1-catalysed estradiol 3β-glucuronidation in human liver microsomes. Biopharm Drug Dispos 2005; 26: 35-39.
17. Forrest JAH, Clements JA, Prescott LF. Clinical pharmacokinetics of paracetamol. Clin Pharmacokinet 1982; 7: 93-107.
18. Gazzard BG, Ford-Hutchinson AW, Smith MJH, Williams R. The binding of paracetamol to plasma protein of man and pig. J Pharm Pharmacol 1973; 25: 964-967.
19. Vietri M, De Santi C, Pietrabissa A, Mosca F, Pacifici GM. Inhibition of human liver phenol sulfotransferase by nonsteroidal anti-inflammatory drugs. Eur J Clin Pharmacol 2000; 56: 81-87.
20. Houin G, Tremblay D, Bree F, Dufour A, Ledudal P, Tillement JP. The pharmacokinetics and availability of niflumic acid in humans. Int J Clin Pharmacol 1983; 21: 130-134.